Summary
• InspireMD Inc. (NSPR) shares rose 12% in pre-market trading to $2.15, following positive developments.
• The CREST-2 study highlighted the efficacy of carotid artery stenting, boosting investor confidence.
• The company approved inducement grants and plans to engage with investors at an upcoming conference.
In the pre-market session, InspireMD Inc. (NSPR) surged to a price of $2.15, marking an impressive 12% gain from its last close at $1.92. The move comes amid heightened interest following recent developments, including compelling results from a notable study published yesterday.
Landmark Study Sparks Investor Interest
On November 24, 2025, InspireMD reported that the landmark CREST-2 study, published in the New England Journal of Medicine, underlined the efficacy of carotid artery stenting combined with medical therapy over intensive medical therapy alone. This study demonstrated a significant reduction in stroke risk for patients with severe asymptomatic carotid stenosis, potentially bolstering confidence in the company’s CGuard® Prime carotid stent system.
Analysts have responded positively, maintaining a “Buy” rating for the stock, which indicates an optimistic outlook among professional investors. The timing of this publication appears to have played a critical role in the pre-market rally.
[chart type=’analyst-ratings’ value=’NSPR’]
Recent Corporate Moves
In addition to the study’s impact, InspireMD announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4) on November 21, 2025. These grants involved approximately 122,054 shares of restricted stock awarded to eight new non-executive employees, signaling the company’s commitment to attracting talent as it continues to innovate within the stroke prevention market.
The company also plans to participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, providing further opportunities to engage with investors and showcase its advancements.
Trading Performance and Volume Insights
NSPR’s stock has been characterized by significant volatility, with a monthly performance decline of 25% and a quarterly drop of nearly 30%. Nonetheless, the current average volume over the past three months stands at 130,460 shares, while the 10-day average is slightly higher at 171,151 shares. This volume data suggests increasing trader engagement as the stock reacts to recent developments.
The current 14-day Relative Strength Index (RSI) sits at 46.74, indicating that the stock is approaching an equilibrium, following a period of increased volatility. The company has also experienced a decline in average weekly performance, seeing a drop of 18% over the past week, which primes investors for this recent upward movement.
[chart type=’price’ value=’NSPR’]
Observing Market Trends
With shares reacting strongly to the informative publishing of the CREST-2 study and the recent corporate developments, investors appear to reassess InspireMD’s growth trajectory. The stock’s performance may continue to draw attention as it reflects on the implications of these new insights in relation to its market position in stroke prevention technologies.